Adial Pharmaceuticals Inc. (ADIL) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear

Adial Pharmaceuticals Inc...

NASDAQ: ADIL · Real-Time Price · USD
0.47
-0.14 (-22.46%)
At close: Jul 30, 2025, 3:59 PM

Adial Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 32.25K 32.25K 32.25K 32.25K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
282.00 423.00 423.00 564.00 564.00 16.26K 31.67K 46.79K 61.63K 60.5K 61.34K 58.36K 57.35K 55.11K 38.72K 26.44K 12.47K
Gross Profit
-141 -282 31.82K 31.68K 31.68K 15.98K -31.67K -46.79K -61.63K -60.5K -61.34K -58.36K -57.35K -55.11K -38.72K -26.44K -12.47K
Operating Income
-8.71M -8.28M -8.13M -7.27M -6.46M -7.54M -9M -10.83M -13.18M -13.32M -16.06M -16.93M -17.51M -19.29M -16.78M -16.05M -13.47M
Interest Income
191.2K 178.66K 136.12K 95.67K 63.69K 69.78K 106.38K 99.61K 87.11K 63.34K 17.72K 17.11K 11.36K 6.54K 5.69K 5.36K 9.36K
Pretax Income
-8.95M -13.2M -13.03M -12.19M -11.24M -7.67M -8.63M -10.39M -12.73M -12.73M -15.79M -17M -17.59M -19.52M -17.06M -16.08M -13.45M
Net Income
-8.95M -13.2M -13.05M -12.24M -8.69M -5.11M -6.05M -7.7M -12.65M -12.52M -15.48M -16.77M -17.35M -19.42M -17.06M -16.08M -13.45M
Selling & General & Admin
5.18M 5.05M 5.36M 5.34M 5.11M 5.96M 6.55M 7.34M 8.92M 9.14M 9.14M 9.56M 9.02M 9.34M 8.65M 7.77M 6.62M
Research & Development
3.52M 3.23M 2.76M 1.94M 1.36M 1.58M 2.45M 3.49M 4.26M 4.18M 5.37M 5.82M 6.94M 8.4M 8.13M 8.28M 6.85M
Other Expenses
n/a -42 51.86K 51.86K -42 n/a -51.9K -51.9K n/a n/a 1.55M 1.57M 1.5M 1.5M -43.8K -61.2K 8.78K
Operating Expenses
8.71M 8.28M 8.13M 7.27M 6.46M 7.54M 9M 10.83M 13.18M 13.32M 14.51M 15.39M 15.96M 17.74M 16.78M 16.05M 13.47M
Interest Expense
n/a n/a 14.89K 14.89K 14.89K 14.89K n/a n/a 17.07K 17.07K 205.22K 205.22K 188.15K 188.15K n/a n/a n/a
Selling & Marketing Expenses
141.00 n/a 1.52M 1.52M 1.52M 1.52M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
6.44M 8.28M 8.13M 7.27M 6.46M 7.54M 9M 10.83M 13.18M 13.32M 14.51M 15.39M 15.96M 17.74M 16.78M 16.05M 13.47M
Income Tax Expense
n/a n/a 15.89K 53.17K -2.54M -2.56M -2.58M -2.69M -76.67K -212.89K -306.46K 43.54K 63.68K 208.22K 302.3K 30.64K -11.75K
Shares Outstanding (Basic)
18.59M 18.59M 5.84M 4.18M 2.95M 1.66M 1.18M 1.13M 1.06M 1.07M 1.03M 972.64K 926.05K 821.14K 793.92K 703.55K 636.48K
Shares Outstanding (Diluted)
18.59M 18.59M 5.84M 4.18M 2.95M 1.66M 1.18M 1.13M 1.06M 1.07M 1.03M 972.64K 926.05K 830.44K 793.92K 703.55K 636.48K
EPS (Basic)
-1.42 -3.27 -4.31 -5.11 -3.56 -4.1 -5.64 -7.41 -12.34 -12.59 -17 -19.49 -21.83 -26.44 -25.37 -26.04 -23.74
EPS (Diluted)
-1.42 -3.27 -4.31 -5.11 -3.56 -4.1 -5.64 -7.41 -12.34 -12.59 -16.92 -19.41 -21.75 -26.36 -25.37 -26.04 -23.74
EBITDA
-8.71M -8.28M -8.25M -7.39M -6.58M -7.01M -8.19M -9.39M -11.15M -11.94M -13.24M -14.75M -15.89M -17.66M -16.75M -16.03M -13.46M
EBIT
-6.44M -8.28M -8.25M -7.39M -6.58M -7.01M -8.34M -10.1M -11.86M -12.65M -13.84M -14.8M -15.96M -17.74M -16.78M -16.05M -13.47M
Depreciation & Amortization
424.00 565.00 565.00 564.00 564.00 16.26K 31.67K 46.79K 61.63K 60.5K 61.34K 58.36K 57.35K 55.11K 38.86K 26.72K 12.89K